The aim of this study was to determine whether the detection of CTC in the apheresis product contribute significantly to treatment failure of patients with highrisk breast carcinoma treated with high-dose chemotherapy (HDC) and stem cell transplantation (SCT). Patients were with stage II and III adenocarcinoma of the breast with у10 axillary lymph nodes affected after primary surgery (у10 N+) who had received HDC with SCT. We analyzed retrospectively the presence of CTC as assessed by immunocytochemistry (ICC) in the apheresis products obtained after standard adjuvant chemotherapy. We compared the clinical outcome of patients who received HDC and SCT with or without CTC-positive apheresis. One hundred and twenty-seven apheresis products samples were obtained from 51 patients. Fourteen (27.4%) of these samples were CTC positive. After a median follow-up of 4.6 years, 20 patients have relapsed, 14 died from progression of their disease and 30 patients remain alive and free of progression. For the whole group of patients the 5 year probabilities of DFS and OS were 60% (IC 95%, 47-75%) and 71% (IC 95%, 55-83%), respectively. However, the 5 year probabilities of DFS were 23% (IC 95%, 0-46) and 75% (IC 95%, 60-89) for patients with CTC positive and negative, respectively. The 5 year probabilities of OS were 42% (IC 95%, 15-68) and 83% (IC 95%, 70-95) for patients with CTC positive and negative, respectively. Both univariate and multivariate analysis showed that the presence of CTC in the apheresis product was the only prognostic factor associated with a higher incidence of clinically overt disease relapse (P = 0.002) and shorter survival (P = 0.003). The presence of cytokeratin-positive metastatic cells in the apheresis product increases the risk of relapse after HDC and SCT in patients with stage II and III adeno- High-dose chemotherapy (HDC) with stem cell transplantation (STC) has been extensively used to treat women with breast cancer based on phase II studies suggesting a clinical benefit in some groups of patients with metastatic, 1-6 and high-risk breast cancer (HRBC).
High-dose chemotherapy (HDC) with stem cell transplantation (STC) has been extensively used to treat women with breast cancer based on phase II studies suggesting a clinical benefit in some groups of patients with metastatic, [1] [2] [3] [4] [5] [6] and high-risk breast cancer (HRBC).
7-11 However, preliminary results from most 12, 13 but not all 14 phase III trials in HRBC patients, suggest no benefit for HDC over conventional treatment. Until the results from currently ongoing phase III trials determine the role of this therapy in patients with breast cancer, identification of new prognostic factors associated with an increased risk of relapse after HDC and SCT may help to define better which patients may benefit from this approach. A number of recent studies have implicated the presence of micrometastatic breast cancer cells in the bone marrow (BM) as an important and independent prognostic factor for relapse after standard chemotherapy. [15] [16] [17] [18] [19] Some studies have suggested a relation between the presence of CTC in the apheresis and relapse after HDC and SCT while other studies, mainly in patients with metastatic disease, have not been able to demonstrate such a relationship. [20] [21] [22] The aim of our study was to assess whether the detection of CTC in the apheresis product of patients with HRBC treated with HDC and SCT, contributes significantly to treatment failure. We have analyzed the presence of CTC by immunocytochemistry (ICC) in the apheresis products of patients with HRBC and compared the clinical outcome after HDC and SCT of patients who received CTC-positive apheresis and those without CTC. Our results show that a relatively high fraction of patients have CTC in PBPC harvests after completing conventional chemotherapy. Furthermore, the presence of micrometastases in the harvests is associated with a higher probability of early relapse in these patients and a decreased DFS and OS.
Bone Marrow Transplantation

Patients and methods
Patients
We studied retrospectively 51 consecutive patients with stage II or III adenocarcinoma of the breast and with high risk of relapse treated at the Hematology and Medical Oncology Department, Hospital Clinico Universitario, University of Valencia, between February 1993 and September 1997. Inclusion criteria included age between 18 and 60 years and WHO performance status 0-1. Cardiac, pulmonary, hepatic, renal and endocrine functions were within normal limits as assessed by clinical examination, chest Xray, EKG and routine serum hepatic and renal chemistries. Serologic tests for human immunodeficiency virus were negative. The base-line diagnostic evaluation for distant metastases included plain chest radiography, mammography of the contralateral breast, ultrasonography of the liver and bone scanning of the entire body. The characteristics of the patients are listed in Table 1 .
Treatment plan
After histopathological diagnosis of breast carcinoma, patients underwent primary surgery (PS). Conservative surgery was performed only in those patients whose planned wide excision with 2 cm around the tumor included less than 20% of the breast volume and achieved microscopically tumor-free margins. All other patients underwent modified radical mastectomy. Axillary lymph node dissec- Mobilization of PBPC was performed by administration of G-CSF (filgrastim; Amgen, Thousand Oaks, CA, USA) alone, 1 month after the last course of standard chemotherapy. Patients received daily doses of G-CSF (10 g/kg/day) and PBPC collections were performed daily starting after the fourth dose of G-CSF until a target cell dose of at least 2.5 × 10 6 CD34 + cells/kg/patient, had been collected. PBPC collections were performed using a CS3000 plus cell separator (Nexell Therapeutics, Irvine, CA, USA). An aliquot was taken from the entire collection of PBPC on the day of apheresis for determination of CD34
+ cell content as previously described 23 and for ICC assay as described below. After sampling, the PBPC harvest was cryopreserved in 10% DMSO and stored in liquid nitrogen.
Patients received conditioning chemotherapy with either CEM (cyclophosphamide 100 mg/kg, etoposide 21 mg/kg, melphalan 140 mg/m 2 ) (n = 24) or STAMP V (cyclophosphamide 6 g/m 2 , thiotepa 500 mg/m 2 , carboplatin 800 mg/m 2 ) (n = 27). 24, 25 On day 0 cryopreserved PBPC were thawed and infused through a central venous access. Patients received G-CSF (5 g/kg/day) after PBPC infusion starting on day +5 until the ANC exceeded 1 × 10 9 /l for 3 consecutive days. Patients received prophylactic antibiotics including norfloxacin, acyclovir and fluconazole from day −6 to discharge. Platelet transfusions and red blood cells transfusions were administered for platelet counts lower than 20 × 10 9 /l or hemoglobin lower than 8.0 g/dl, respectively.
After engraftment, stage II-III patients received locoregional radiation therapy starting no sooner than 4 weeks after PBPC infusion provided the WBC count was у3 × 10 9 /l and platelet count was у50 × 10 9 /l. A total dose of 50 Gy was administered to the involved breast or ipsilateral chest wall and the supraclavicular fossa. Tamoxifen (20 mg daily for 5 years) was given to women whose tumors were estrogen receptor (ER) or progesterone receptor (PR) positive, or unknown. The initial evaluation was repeated after the completion of the standard chemotherapy, before the SC mobilization. Patients were reevaluated at days +30, +60 and +90 after stem cell transplant and, subsequently, every 3 months during the first 3 years, and every 6 months thereafter with physical examination, blood chemistries, and complete blood cell and platelet counts together with chest X-rays. Annual mammograms, bone scans and liver ultrasound were performed.
Detection of contaminating tumor cells
Assessment of tumor cells was done in patient samples obtained from thawed cryopreserved apheresis products. Samples were diluted with autologous plasma and 10% DMSO (concentration adjusted to 100 × 10 6 cells/ml), frozen at a controlled rate and stored at −80°C. Cryopre-served samples were rapidly thawed in a 37°C waterbath, incubated with dornase alpha (Pulmozyme; Hoffmann-La Roche, Basel, Switzerland) at 10 U/ml for 30 min to prevent clotting, and washed twice with serum-free RPMI-1640 medium supplemented with heparin and centrifuged at 400 g for 5 min. The mononuclear cells were resuspended at a cell dilution of 1 × 10 6 cells in 1.2 ml PBS. The ICC staining procedure for the detection of tumor cells on cytospin preparations was done using the Epimet epithelial cell detection kit according to the manufacturer's instructions (Micromet, Munich, Germany) 26 and following the recommendations for evaluation of immunostained cells established by the ISHAGE Standardization Working Group. 27 Briefly, mononuclear cells were attached to previously cleaned (1% HCl in 70% ethanol) and poly-lLysine (Sigma, Poole, UK)-coated adhesion slides. Four slides were examined for each patient, with 5 × 10 5 cells each (a total of 2 × 10 6 cells analyzed/sample/patient). After 10 min the slides were rinsed with PBS to remove dead cells and cellular debris. Subsequently cells were air-dried for 24 h. Mononuclear cells were incubated with an immunoglobulin G 1 murine monoclonal antibody (A45-B/B3) directed against a common epitope of cytokeratins, including CK 8-18 and CK8-19 heterodimers, which are integral components of the epithelial cytoskeleton, and using the alkaline phosphatase anti-alkaline phosphatase (APAAP) assay. Cells containing cytokeratin components were stained bright red without a background reaction. A cell was considered ICC positive when immunostaining was observed on at least 75% of the cell membrane and cytoplasm and morphology was consistent with a malignant cell. Slides were examined by two observers. Discrepancies in ICC results were resolved by additional immunostaining experiments and joint decision. Samples were scored as positive if there was one or more cells positive for cytokeratin staining. The breast cancer MCF-7 cell line was used as a positive control and the lymphoma Jurkat cell line as a negative control (American Type Cultured Collection, ATCC, Rockville, MD, USA).
Statistical methods
Distribution of time-to-event data was estimated using the Kaplan-Meier method 28 for categorical variables, and compared statistically using the log-rank test. For continuous variables we used Cox regression analysis and the Wald's statistic to test if the estimated coefficient was different from 0. Multivariate analysis was performed using a forward stepwise conditional Cox proportional hazards model. All tests were performed at the 0.05 level of significance.
OS and DFS were calculated from the day of diagnosis. OS was defined as time to death from any cause. DFS was defined as time to recurrence. Transplant-related mortality was defined as death at any time not due to recurrence. Statistical analyses were performed with SPSS statistical software (SPSS, Chicago, IL, USA).
Results
The median number of PBPC collections performed were 2 (range 1-5) with a median number of CD34
+ cells of 4.65
Bone Marrow Transplantation × 10 6 /kg (range, 1.68-27). All patients engrafted and were evaluable for relapse. One patient died due to transplantrelated complications on day +50 (1/51, 1.9%). After a median follow-up of 55 months (8-91 months), 20 patients have relapsed, 14 died from progression of their disease and 30 patients remain alive and free from progression. The five year probabilities of DFS and OS were 60% (IC 95%, 47-75%) and 71% (IC 95%, 55-83%), respectively. Micrometastases were found in the aphereses of 14 out of 51 studied patients (27.4%). The following potential prognostic factors for relapse and survival were examined: age, menopausal status, T pathology, number of LN affected at diagnosis, pathological stage (stage II-III), histological grade (2-3), ER and PR status, type of HDC protocol (STAMP-V vs CEM), and presence of CTC in the apheresis sample. By univariate analysis, the risk of relapse was lower only for patients receiving aphereses with no CTC (Table 2 ). Ten out of 14 patients (71%) who received CTC positive aphereses have relapsed, while only 10 of the 37 patients (27%) with CTC negative aphereses relapsed (P = 0.002, log-rank test). Overall survival was also negatively affected by the presence of CTC in the apheresis products (P = 0.003, log-rank test) (Figure 1) . The 5 year probabilities of DFS were 23% (IC 95%, 0-46) and 75% (IC 95%, 60-89) for patients with CTC-positive and -negative aphereses, respectively. The 5 year probabilities of OS were 42% (IC 95%, 15-68) and 83% (IC 95%, 70-95) for patients with CTC-positive and -negative aphereses, respectively. Interestingly, differences in DFS could only be detected after 2 years of follow-up.
No association was detected between the number of apheresis procedures done in each patient and a more frequent CTC positivity (one of one patient with one apheresis procedure, 100%; seven of 31 patients who needed two apheresis procedures, 23%; four of 13 patients with three apheresis procedures, 31%; two of five patients who needed four apheresis procedures, 40%; and none of one patient with five apheresis procedures) (P = 0.4) (Figure 2) . However, because the number of leukaphereses was determined by the achievement of the target CD34
+ cell dose, the number of patients with more than two procedures was small and limited the potential detection of a significant association of CTC-positive detection with the number of apheresis procedures.
The multivariate stepwise Cox regression analysis, including age, number of affected nodes, histological grade, hormone receptor status and the presence of CTC in the apheresis sample, identified only the presence of CTC in the apheresis sample as an independent prognostic factor for relapse (relative risk of relapse 9.8, 95% CI, 2.5-38) (P Ͻ 0.01) ( Table 3) . Although not statistically significant, the number of affected nodes showed a trend toward an increased risk of relapse (P = 0.06) when analyzed both as continous or categorical (10-14, 15-19 and more than 19 nodes) variables. When categorized, the increased probability of relapse was associated with the small group of patients with the highest number of affected nodes (patients with 10-14 N+ vs 15-19 N+, P = 0.69; patients with 10-14 N+ vs Ͼ19 N+, P = 0.005). 
Table 3
Multivariate analysis of potential factors influencing DFS in patients with high-risk breast cancer with у10 axillary affected nodes treated with HDC followed by SCT 
Discussion
The potential advantage of treatment with HDC and SCT in patients with HR breast cancer is based on preclinical [29] [30] [31] and phase II studies. 6,7,10 Recently, the preliminary results of randomized trials including patients with high risk of relapse and metastases 12,13 has been reported. Although these studies have not shown a significant difference in OS and DFS between patients undergoing HDC vs standard chemotherapy, further follow-up and the results of other ongoing studies are needed before definitive conclusions can be drawn.
While definitive results of randomized trials are pending, it is important to identify subgroups of HRBC patients who may benefit from HDC and SCT as currently delivered. Some studies have addressed prognostic factors for relapse after HDC and PBPCT. 3, 20, [32] [33] [34] [35] [36] [37] [38] [39] In the analysis by Somlo et al 37 of HRBC patients treated with two different HDC, PR negativity was the only independent prognostic factor of relapse. Nieto et al 39 described a predictive model using a scoring system that include the nodal ratio, tumor size and the ER/PR status.
The increase in the number of patients treated with HDC and SCT for patients with BC has generated concern about the infusion of tumor cell contamination in the graft. In an effort to study so-called minimal residual disease (MRD), a variety of assay methods have been developed. Although these assays vary in terms of sensitivity and specificity of tumor detection, they are consistent with the presence and viability of tumor cells in the grafts detected by other methods. A growing body of evidence indicates that MRD is present in autologous grafts from breast cancer patients and that these tumor cells appear to be capable of clonogenic growth at least in vitro. 40, 41 Gene-marking studies in the setting of autologous hematopoietic stem cell transplantation for malignancies other than breast cancer have demonstrated that infused tumor cells are present at sites of disease relapse. 42, 43 Given the availability of methods of passive purging of tumor cells, 44, 45 both in vitro and clinical demonstration of the importance of infused CTC would be the base to use these methods of cellular selection.
Over the last several years, different methods for detection of MRD have been developed. Immunostaining of epithelial tissue-specific components using monoclonal antibodies against cytokeratins has become the standard method for detection of such cells. 46 Various epithelial tumor cell immunocytochemical assays, including our own, have been shown to detect as few as one tumor cell in 10 5 hematopoietic cells and appear comparable to polymerase chain reaction techniques for cytokeratin or epidermal growth factor receptors. 41, 47, 48 Using these sensitive molecular and immunocytochemical techniques, microscopic tumor involvement has been identified in 10% to 80% of PBPC collections and 60% to 80% of histologically normal bone marrow harvest obtained from HRBC and stage IV breast cancer patients. 41, 46, 49, 50 In our study CTC cells were detected in 27.4% of aphereses which is consistent with other reports. Differences between different studies may be related to the PBPC mobilization method, and the evaluation of the immunostained cells. The recently published Bone Marrow Transplantation criteria by the European ISHAGE Working Group on Standardization of Tumor Cell Detection may be extremely useful to normalize the results of these studies. 27 Studies that addressed the clinical significance of the reinfusion of tumor cells in the apheresis products as assessed by ICC methods have provided contradictory information. [20] [21] [22] 34, 36, 51 Interestingly, most studies that analyzed metastatic patients did not find a significant correlation between occult tumor reinfusion and time to progression or overall survival 21, 22 while a correlation has been observed more frequently in non-metastatic patients. 20, 51 In addition, the majority of patients with metastatic disease developed progression in prior metastatic sites rather than in new locations. Both observations suggest that when we are treating a subgroup of patients with a relatively high and chemoresistant residual tumor burden, the inadequate tumor cytoreduction makes it difficult to detect the potential influence of the infusion of tumor. In contrast, the studies which analyze patients with high risk of relapse stage II and III breast cancer, potentially with a more limited and chemosensitive residual tumor burden, more often have found that the presence of tumor cells in the infused hematopoietic support predicted relapse. Whether CTC represent a biologic marker of residual tumor burden, rather than contribute directly to relapse is unknown. It is possible that the introduction of quantitative methods to assess minimal residual disease may provide additional information in this field.
It has been shown that the peak hazard of recurrence in breast cancer after primary surgery occurs in the interval of 1 to 2 years later. This hazard decreases consistently in the interval of 2 to 5 years and the average hazard of recurrence between years 5 and 12 is 4.3% per year. 52, 53 This suggests that most of the progressions and deaths happened during the first 4 years after therapy. In the present study, with a median follow-up of 55 months, 71% of the patients remain alive and 60% remain free of disease. Interestingly, if we analyze the pattern of relapse of patients with and without infusion of CTC included in the present study, it is different only after the first 2 years from diagnosis, suggesting that the early relapses could be due to residual resistant disease, while late relapses could be related to the tumor cells infused.
In summary, despite the limited number of patients, this study suggests that the presence of CTC in the apheresis products increases the probability of relapse after HDC and SCT in patients with HRBC with у10 affected nodes at diagnosis. 
